

Scientific Program and Conference Schedule

Saturday, November 12, 2011

1:30 p.m.-3:30 p.m. Educational Session 1: Treatment of Premalignant Conditions

Ballroom, Third Floor

Chairperson: Scott M. Lippman, University of Texas
MD Anderson Cancer Center, Houston, TX, USA

Preventing multiple types of cancer through HPV
vaccination*

Douglas R. Lowy, National Cancer Institute,
Bethesda, MD, USA

Chemoprevention of lung cancer with prostacyclins or
PPAR gamma agonists*

Paul A. Bunn Jr., University of Colorado Denver,
Aurora, CO, USA

Use of presurgical models to screen active agents for
breast intraepithelial neoplasia*

Andrea De Censi, E.O. Ospedali Galliera, Genoa,
Italy

Cancer interception and reverse migration

Scott M. Lippman

3:30 p.m.-5:30 p.m. Educational Session 2: Clinical Trial Paradigms in the Era of Novel Therapies

Ballroom, Third Floor

Chairperson: James H. Doroshov, National Cancer
Institute, Bethesda, MD, USA

New paradigms for early-phase clinical trials

James H. Doroshov

Phasing out phase III trials: How much evidence do
we need if the target is clearly hit?*

Jaap Verweij, Erasmus University Medical Center,
Daniel den Hoed Cancer Center, Rotterdam,
The Netherlands

Development of clinical trials incorporating genomic
signatures: Lessons learned*

Lisa M. McShane, National Cancer Institute,
Bethesda, MD, USA

Clinical trial designs for targeted therapies

John J. Crowley, Cancer Research and Biostatistics,
Seattle, WA, USA

5:30 p.m.-7:00 p.m. Networking Reception

Grand Ballroom,
InterContinental Hotel

Sunday, November 13, 2011

7:00 a.m.-8:00 a.m. Continental Breakfast

Third Floor Foyer

8:00 a.m.-10:05 a.m. Opening Plenary Session: Opening Remarks and Keynote Lectures

Ballroom, Third Floor

Co-Chairpersons: Kenneth C. Anderson, Dana-
Farber Cancer Institute, Boston, MA, USA, **James H.
Doroshov**, National Cancer Institute, Bethesda, MD,
USA, and **Stefan Sleijfer**, Erasmus Medical Center,
Rotterdam, The Netherlands

Overcoming barriers to new drug development*

William N. Hait, Johnson & Johnson Pharmaceutical
Research and Development, Raritan, NJ, USA

Genomic profiling for personalized medicine

Andy Futreal, Wellcome Trust Sanger Institute,
Hinxton, United Kingdom

10:05 a.m.-10:30 a.m. Coffee Break

Third Floor Foyer

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

**10:30 a.m.-12:30 p.m. Plenary Session 1:
Novel Clinical Paradigms
in Personalized Medicine**
Ballroom, Third Floor

Chairperson: José Baselga, Massachusetts General Hospital Cancer Center, Boston, MA, USA

Combinatorial approaches to prevent adoptive responses to targeted therapeutics in breast cancer

José Baselga

Optimizing targeted treatment of EGFR mutant lung cancer

William Pao, Vanderbilt University, Nashville, TN, USA

Predicting response and resistance to targeted anticancer therapeutics

Levi A. Garraway, Dana-Farber Cancer Institute, Boston, MA, USA

The neoadjuvant model in breast cancer research: Stories of success*

Serena Di Cosimo, Vall d'Hebron University Hospital, Barcelona, Spain

12:30 p.m.-2:30 p.m. Poster Session A
Exhibit Hall, First Floor

Angiogenesis and Antiangiogenesis Agents 1

Animal Models 1

Apoptosis, Necrosis, and Autophagy

Bioinformatics

Biomarkers 1

Cancer Stem Cells 1

Cell Cycle Regulators

Cellular Responses to Therapy 1

Chemoprevention

Clinical Trials 1

Differentiation

DNA Repair and Modulation 1

Drug Delivery

Drug Design

Drug Metabolism, Transport, and Biodistribution

Drug Screening

EGFR/Her2

Epigenetic Targets 1

mTOR/PI3-Kinase 1

New Molecular Targets 1

Pharmacokinetics and Pharmacodynamics 1

Target Identification and Validation 1

Therapeutic Agents: Biological 1

Therapeutic Agents: Other 1

Therapeutic Agents: Small Molecule

Kinase Inhibitors 1

12:30 p.m.-7:30 p.m. Exhibit Show
Exhibit Hall, First Floor

**2:30 p.m.-4:30 p.m. Plenary Session 2:
Lessons from the
BRAF-Targeted Therapy
of Melanoma**
Ballroom, Third Floor

Chairperson: Neal Rosen, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Changing cell fate in cancer: Lessons from melanoma*

Leonard I. Zon, Harvard Medical School, Children's Hospital, Boston, MA, USA

BRAF and RAS signaling in cancer: From biology to therapeutics*

Richard M. Marais, Institute of Cancer Research, London, United Kingdom

BRAF and MEK inhibition in melanoma

Tona M. Gilmer, GlaxoSmithKline, Research Triangle Park, NC, USA

Title to be announced

Neal Rosen

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

Scientific Program and Conference Schedule

4:30 p.m.-6:00 p.m. **Proffered Paper Session 1**
Ballroom, Third Floor

Chairperson: Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA, USA

PR-1 Acquired resistance to RAF inhibitors is mediated by splicing isoforms of BRAF(V600E) that dimerize in a RAS-independent manner**

Poulikos I. Poulikakos, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

PR-2 KRAS mutation and amplification status predicts sensitivity to antifolate therapies in non-small cell lung cancer**

Sarah Bacus, Quintiles Transnational Corporation, Westmont, IL, USA

PR-3 Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: Association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib**

Elizabeth Punnoose, Genentech, Inc., South San Francisco, CA, USA

PR-4 Gene amplification of anaplastic lymphoma kinase in inflammatory breast cancer**

Fredika M. Robertson, University of Texas MD Anderson Cancer Center, Houston, TX, USA

PR-5 GATA2 is required for oncogene-driven non-small cell lung cancer*

Madhu S. Kumar, CRUK London Research Institute, London, United Kingdom

PR-6 Pharmacodynamic analysis of ENCORE 301, a placebo-controlled, randomized phase 2 study of exemestane with and without entinostat in postmenopausal ER+ breast cancer patients demonstrates an association of lysine hyperacetylation with clinical outcome**

Peter Ordentlich, Syndax Pharmaceuticals, Inc., Waltham, MA, USA

6:00 p.m.-7:30 p.m. **Poster Session A (continued)**
Exhibit Hall, First Floor

Monday, November 14, 2011

7:00 a.m.-8:00 a.m. **Continental Breakfast**
Third Floor Foyer

8:00 a.m.-10:00 a.m. **Plenary Session 3: Developing Novel Validated Preclinical Models**
Ballroom, Third Floor

Chairperson: Emma M. Lees, Novartis Institutes for BioMedical Research, Emeryville, CA, USA

Discovery of candidate biomarkers of anticancer drug sensitivity by high-throughput cell line screening*

Cyril Benes, Massachusetts General Hospital Cancer Center, Charlestown, MA, USA

Building more predictive in vitro and in vivo models to identify responder populations preclinically

Emma M. Lees

Developing pancreatic cancer medicine

David A. Tuveson, Cancer Research UK, Cambridge, United Kingdom

Genetic and preclinical interrogation of genetically engineered mouse models of lung cancer

Leisa Johnson, Genentech, Inc., South San Francisco, CA, USA

10:00 a.m.-10:30 a.m. **Coffee Break**
Third Floor Foyer

10:30 a.m.-12:30 p.m. **Plenary Session 4: Mechanistic-Based Immunotherapy**
Ballroom, Third Floor

Chairperson: Cornelis J. M. Melief, Leiden University Medical Center, Leiden, The Netherlands

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

**An extended abstract for this presentation is available in the Proffered Papers section of the *Proceedings*.

Sipuleucel-T and the active immunotherapy of prostate cancer*
David L. Urdal, Dendreon Corporation, Seattle, WA, USA

Development of ipilimumab (anti-CTLA-4) and beyond: Contribution to a new immunotherapy paradigm
Axel Hoos, Bristol-Meyers Squibb, Wallingford, CT, USA

Engineering improved cancer vaccines*
Glenn Dranoff, Dana-Farber Cancer Institute, Boston, MA, USA

Synthetic long peptide vaccines against established disease caused by high-risk human papillomavirus*
Cornelis J. M. Melief

12:30 p.m.-2:30 p.m. Poster Session B
Exhibit Hall, First Floor

Angiogenesis and Antiangiogenesis Agents 2

Animal Models 2

Biomarkers 2

Cellular Responses to Therapy 2

Clinical Trials 2

DNA Repair and Modulation 2

Drug Resistance and Modifiers 1

Epigenetic Targets 2

Gene Therapies

Genomics, Proteomics, and Target Discovery

Heat Shock Proteins

Hormonal Agents and Therapy

Imaging

In Vitro and In Vivo Models for Targets

MAPK Pathways

Metabolism

Metastasis and Invasion 1

mTOR/PI3-Kinase 2

Natural Products

New Molecular Targets 2

Pharmacokinetics and Pharmacodynamics 2

Target Identification and Validation 2

Therapeutic Agents: Biological 2

Therapeutic Agents: Other 2

Therapeutic Agents: Small Molecule Kinase Inhibitors 2

12:30 p.m.-7:30 p.m. Exhibit Show
Exhibit Hall, First Floor

**2:30 p.m.-4:30 p.m. Concurrent Session 1:
Finding the Best New
Cancer Targets**
Rooms 2001-2005,
Second Floor

Chairperson: Paul Workman, Institute of Cancer Research, Sutton, United Kingdom

Finding the best new cancer targets:
Approaches and challenges

Paul Workman

canSAR: An integrated cancer drug discovery informatics platform allowing systematic target evaluation*

Bissan Al-Lazikani, Cancer Research UK, Sutton, United Kingdom

Identification of high-value targets for oncology drug discovery: Cancer genetics, synthetic lethality, and beyond

Markus Warmuth, H3 Biomedicine, Cambridge, MA, USA

Identifying druggable targets from alterations in the cancer genome

Matthew L. Meyerson, Dana-Farber Cancer Institute, Boston, MA, USA

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

Scientific Program and Conference Schedule

**2:30 p.m.-4:30 p.m. Concurrent Session 2:
Mechanism-Based
Targeted Combination
Therapies**

Rooms 2007-2011,
Second Floor

Chairperson: William C. Hahn, Dana-Farber Cancer Institute, Boston, MA, USA

Functional genomics to identify targets and resistance*

William C. Hahn

Dual inhibition of mTOR and IGFR pathways*

Scot W. Ebbinghaus, Merck Research Laboratories, North Wales, PA, USA

Targeting epigenomic and apoptotic proteins and pathways to treat leukemia and lymphoma

Ricky W. Johnstone, Peter MacCallum Cancer Center, Melbourne, Australia

Mechanisms of resistance to receptor tyrosine kinase inhibitors revealed through functional genetic screens

René Bernards, The Netherlands Cancer Institute, Amsterdam, The Netherlands

**2:30 p.m.-4:30 p.m. Concurrent Session 3:
Challenges in PI3K
Inhibition**

Rooms 2014-2018,
Second Floor

Chairperson: Jean-Charles Soria, Institut Gustave-Roussy, Villejuif, France

Mechanistic basis for treatment combinations with PI3K inhibitors*

Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA

Clinical development strategies of PI3K inhibitors

Mika Derynck, Genentech, Inc., South San Francisco, CA, USA

Title to be announced

Patricia M. LoRusso, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA

PI3K pathway inhibitors: How deep should we go?*

Josep Tabernero, Vall d'Hebron University Hospital, Barcelona, Spain

**2:30 p.m.-4:30 p.m. Concurrent Session 4:
Pharmacogenomics and
Pharmacogenetics**

Rooms 2020-2024,
Second Floor

Chairperson: Henk-Jan Guchelaar, Leiden University Medical Center, Leiden, The Netherlands

Contribution of polymorphic transporters to oncology drug disposition and safety*

Alex Sparreboom, St. Jude Children's Research Hospital, Memphis, TN, USA

Interrogating the heritable genome to achieve the goal of personalized cancer therapeutics*

Federico Innocenti, University of North Carolina, Chapel Hill, NC, USA

Somatic driver mutations as a guide for anticancer treatment in lung cancer

Bruce E. Johnson, Dana-Farber Cancer Institute, Boston, MA, USA

Pharmacogenetic findings translated into clinical predictive biomarkers*

Henk-Jan Guchelaar

**4:30 p.m.-6:00 p.m. Proffered Paper Session 2:
Ballroom, Third Floor**

Chairperson: Stefan Sleijfer, Erasmus Medical Center, Rotterdam, The Netherlands

PR-7 Anti-tumor activity of the immunomodulatory peptide SCV-07 correlates with changes in macrophage STAT3 signal transduction and cytokine secretion**

Jackie Papkoff, SciClone Pharmaceuticals, Foster City, CA, USA

PR-8 Development of a multiplex panel of putative biomarkers for assessing pharmacodynamic effects of anticancer therapies targeting apoptosis**

Apurva K. Srivastava, SAIC-Frederick, Frederick, MD, USA

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

**An extended abstract for this presentation is available in the Proffered Papers section of the *Proceedings*.

PR-9 Characterization of colon cancer associated antigens which would be key therapeutic targets in the prevention of disease relapse or progression**
Elizabeth K. Broussard, University of Washington, Seattle, WA, USA

PR-10 PARP inhibition induces genomic instability in normal human cells**
Shuhei Ito, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

PR-11 Pharmacogenomics of mTOR inhibitors: A genome-wide association approach of biomarker identification**
Jing Jiang, Mayo Clinic, Rochester, MN, USA

PR-12 Loss of the retinoblastoma protein alters glucose and glutamine metabolism**
Brian F. Clem, University of Louisville, Louisville, KY, USA

6:00 p.m.-7:30 p.m. **Poster Session B (continued)**
Exhibit Hall, First Floor

Tuesday, November 15, 2011

7:00 a.m.-8:00 a.m. **Continental Breakfast**
Third Floor Foyer

8:00 a.m.-10:00 a.m. **Plenary Session 5:
The Epigenome as a
Therapeutic Target**
Ballroom, Third Floor

Chairperson: Robert Brown, Imperial College London, London, United Kingdom

MMSET: A pathogenic factor and therapeutic target in multiple myeloma*
Jonathan D. Licht, Northwestern University Lurie Comprehensive Cancer Center, Chicago, IL, USA

Novel agents for epigenetic therapy
Jean-Pierre J. Issa, Fels Institute for Cancer Research and Molecular Biology, Temple University, Philadelphia, PA, USA

Molecular basis and novel options for alternative epigenetic treatments against cancer*
Lucia Altucci, Seconda Università Degli Studi di Napoli, Department Patologia Generale, Naples, Italy

Epigenetic marks as biomarkers and their mechanisms of maintenance as targets in ovarian cancer*
Robert Brown

10:00 a.m.-10:30 a.m. **Coffee Break**
Third Floor Foyer

10:30 a.m.-12:30 p.m. **Plenary Session 6:
Targeting Tumor Stroma
Interaction**
Ballroom, Third Floor

Chairperson: Nadia Harbeck, University Hospital of Cologne, Cologne, Germany

Impact of breast tumor microenvironment on treatment efficacy
Fabrice Andre, Institut Gustave Roussy, Villejuif, France

Premetastatic niche: Opportunity for early intervention?
David C. Lyden, Weill Cornell Medical College, New York, NY, USA

Urokinase plasminogen activator system: A multifunctional drug target*
Nadia Harbeck

Targeting the tumor ecosystem: Translating the molecular biology of chemokine interactions to the clinic*

Kenneth J. Pienta, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

**An extended abstract for this presentation is available in the Proffered Papers section of the *Proceedings*.

Scientific Program and Conference Schedule

12:30 p.m.-2:30 p.m. Poster Session C
Exhibit Hall, First Floor

Biomarkers 3
Clinical Trials 3
Drug Resistance and Modifiers 2
Metastasis and Invasion 2
Molecular Classification of Tumors
Monoclonal Antibodies
mTOR/PI3-Kinase 3
New Molecular Targets 3
Novel Assay Technology
Other
Pediatric: Early Drug Development
Pharmacogenetics, Pharmacogenomics, and Therapeutic Response
Pharmacokinetics and Pharmacodynamics 3
Protein-Protein Interaction
Radiotherapeutics
RNA and RNA-Based Technologies and Therapies
Signal Transduction Modulators
Target Identification and Validation 3
Therapeutic Agents: Biological 3
Therapeutic Agents: Other 3
Therapeutic Agents: Small Molecule Kinase Inhibitors 3
Topoisomerase Inhibitors
Toxicology
Tubulin-Interacting Agents
Tumor Immunology Targets
Tumor Microenvironment
Tumor Suppressors
Vaccines

12:30 p.m.-6:00 p.m. Exhibit Show
Exhibit Hall, First Floor

**2:30 p.m.-4:30 p.m. Concurrent Session 5:
Targeting DNA
Damage Response**
Rooms 2001-2005,
Second Floor

Chairperson: Beverly A. Teicher, National Cancer Institute, Rockville, MD, USA

Targeting Mdm2 in DNA repair and chromosome instability*

Christine M. Eischen, Vanderbilt University, Nashville, TN, USA

Targeting the Fanconi anemia/BRCA pathway in cancer therapy*

Alan D. D'Andrea, Dana-Farber Cancer Institute, Boston, MA, USA

Targeting molecular chaperones to induce telomere dysfunction

Shawn E. Holt, Virginia Commonwealth University, Richmond, VA, USA

Opportunities for targeting homologous recombination in human cancers*

Simon N. Powell, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

**2:30 p.m.-4:30 p.m. Concurrent Session 6:
Inhibition of Stem
Cell Signaling**
Rooms 2007-2011,
Second Floor

Chairperson: Daniel D. Von Hoff, Translational Genomics Research Institute, Phoenix, AZ, USA

Low-dose azacytidine and epigenetic regulation of self-renewal*

Cynthia A. Zahnow, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

TGF-beta and cancer stem cells*

Joan Seoane, Vall d'Hebron Institute of Oncology, Barcelona, Spain

Regulation of breast cancer stem cells by cytokine networks*

Max S. Wicha, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA

The hedgehog signaling pathway in cancer*

William H. Matsui, Johns Hopkins University School of Medicine, Baltimore, MD, USA

2:30 p.m.-4:30 p.m.

**Concurrent Session 7:
Challenges in Genomic-
Based Characterization
of Tumors**

Rooms 2014-2018,
Second Floor

Chairperson: Lynda Chin, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Accessing and using data from the International Cancer Genome Consortium (ICGC) to get insights into cancer genomes

Francis Ouellette, Ontario Institute for Cancer Research, Toronto, ON, Canada

Target discovery with OncoPrint: Discovering new targets and positioning old targets by integrative analysis of 10,000s of tumor genomes and transcriptomes*

Daniel R. Rhodes, Compendia Bioscience, Ann Arbor, MI, USA

Translating the cancer genome

Lynda Chin

Patient-specific pathway analysis using PARADIGM identifies key activities in multiple cancers*

Joshua M. Stuart, University of California, Santa Cruz, CA, USA

2:30 p.m.-4:30 p.m.

**Concurrent Session 8:
Advances in Targeted
Hormonal Therapies**

Rooms 2020-2024,
Second Floor

Chairperson: Johann S. de Bono, Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

Targeting the androgen receptor in castration-resistant prostate cancer*

Donald J. Tindall, Mayo Clinic College of Medicine, Rochester, MN, USA

Androgens, biomarkers, and abiraterone*

Johann S. de Bono

Neoadjuvant androgen deprivation therapy for high-risk prostate cancer

Mary-Ellen Taplin, Dana-Farber Cancer Institute, Boston, MA, USA

A combinatorial approach to targeting androgen receptor signaling in prostate cancer*

Wayne D. Tilley, University of Adelaide, Adelaide, Australia

4:30 p.m.-6:00 p.m.

**Poster Session C
(continued)**

Exhibit Hall, First Floor

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

Scientific Program and Conference Schedule

Wednesday, November 16, 2011

7:00 a.m.-8:00 a.m. **Continental Breakfast**
Third Floor Foyer

8:00 a.m.-10:00 a.m. **Plenary Session 7:
Rational Cancer Drug
Development for Targeted
Drugs: The Interface
Between Industry,
Academia, and Regulators**
Ballroom, Third Floor

Chairperson: Frank McCormick, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

Rational cancer drug development for targeted drugs: Views from academia and the European Medicines Agency (EMA)*

Jonas C.S. Bergh, Karolinska Institutet and University Hospital, Stockholm, Sweden

Rational cancer drug development for targeted drugs*
Richard B. Gaynor, Eli Lilly and Company, Indianapolis, IN, USA

FDA role in smoothing the progress of targeted drug development

Anthony J. Murgo, Food and Drug Administration (FDA), Center for Drug Evaluation and Research, Silver Spring, MD, USA

Panelists:

Iordanis Gravanis, European Medicines Agency, London, United Kingdom

Christopher J. Logothetis, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Eric H. Rubin, Merck Research Laboratories, North Wales, PA, USA

10:00 a.m.-10:30 a.m. **Coffee Break**
Third Floor Foyer

10:30 a.m.-12:30 p.m. **Plenary Session 8:
Targeting Tumor
Metabolism**
Ballroom, Third Floor

Chairperson: Christian Dittrich, Ludwig Boltzmann Institute for Applied Cancer Research, Vienna, Austria

Clinical achievements reached by interfering with the IGF1R-PI3K-PTEN-AKT-mTOR axis*

Christian Dittrich

HIF-1 and reprogramming of cancer cell metabolism: Opportunities for therapy

Giovanni Melillo, Bristol-Myers Squibb, Princeton, NJ, USA

Is there a role for metformin in cancer therapeutics?
Ana M. Gonzalez-Angulo, University of Texas MD Anderson Cancer Center, Houston, TX, USA

New ways to impact glutamine metabolism in cancer*
Richard A. Cerione, Cornell University, Ithaca, NY, USA

12:30 p.m.-12:45 p.m. **Closing Remarks**
Ballroom, Third Floor

*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.